NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that on January 29, 2009, the Company entered into definitive agreements to sell restricted common stock and warrants for aggregate gross proceeds of $1,200,000.
